{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:06:11Z","timestamp":1740175571173,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Manitoba Centre for Health Policy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.17269\/s41997-019-00240-1","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T15:02:46Z","timestamp":1562857366000},"page":"705-713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Latent tuberculosis treatment completion rates from prescription drug administrative data"],"prefix":"10.17269","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-4335","authenticated-orcid":false,"given":"Pierre J.","family":"Plourde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Basham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley","family":"Derksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Larcombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathi Avery","family":"Kinew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Lix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"issue":"11","key":"240_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf, H., Hill, P. C., Matteelli, A., et al. (2016). The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. The Lancet Infectious Diseases, 16(11), 1269\u20131278.","journal-title":"The Lancet Infectious Diseases"},{"issue":"7","key":"240_CR2","doi-asserted-by":"publisher","first-page":"e100975","DOI":"10.1371\/journal.pone.0100975","volume":"9","author":"GG Alvarez","year":"2014","unstructured":"Alvarez, G. G., VanDyk, D. D., Aaron, S. D., et al. (2014). TAIMA (stop) TB: the impact of a multifaceted TB awareness and door-to-door campaign in residential areas of high risk for TB in Iqualuit, Nunavut. PLoS One, 9(7), e100975. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0100975\n\n.","journal-title":"PLoS One"},{"key":"240_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/thx.2009.125054","volume":"65","author":"A Aspler","year":"2010","unstructured":"Aspler, A., Long, R., Trajman, A., et al. (2010). Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax., 65, 582\u2013587.","journal-title":"Thorax."},{"issue":"5","key":"240_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40(5), 373\u2013383.","journal-title":"Journal of Chronic Diseases"},{"issue":"3","key":"240_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.14745\/ccdr.v43i34a04","volume":"43","author":"V Gallant","year":"2017","unstructured":"Gallant, V., Duvvuri, V., & McGuire, M. (2017). Tuberculosis in Canada \u2013 summary 2015. Canada Communicable Disease Report, 43(3), 77\u201382.","journal-title":"Canada Communicable Disease Report"},{"key":"240_CR6","unstructured":"Health Canada, Drugs and Health Products, Access to Drugs in Exceptional Circumstances. List of drugs for an urgent public health need. February 2018. (accessed May 2019 at \nhttps:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/access-drugs-exceptional-circumstances\/list-drugs-urgent-public-health-need.html\n\n)."},{"issue":"1","key":"240_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5588\/ijtld.14.0373","volume":"19","author":"Y Hirsch-Moverman","year":"2015","unstructured":"Hirsch-Moverman, Y., Shrestha-Kuwahara, R., Bethel, J., et al. (2015). Latent tuberculous infection in the United States and Canada: who completes treatment and why? The International Journal of Tuberculosis and Lung Disease, 19(1), 31\u201338.","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"issue":"2","key":"240_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1378\/chest.09-0394","volume":"137","author":"CR Horsburgh Jr","year":"2010","unstructured":"Horsburgh, C. R., Jr., Goldberg, S., Bethel, J., et al. (2010). Latent TB infection treatment acceptance and completion in the United States and Canada. Chest, 137(2), 401\u2013409.","journal-title":"Chest"},{"issue":"5","key":"240_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1155\/2014\/349138","volume":"25","author":"K Malejczyk","year":"2014","unstructured":"Malejczyk, K., Gratrix, J., Beckon, A., et al. (2014). Factors associated with noncompletion of latent tuberculosis infection treatment in an inner-city population in Edmonton, Alberta. The Canadian Journal of Infectious Diseases & Medical Microbiology AMMI Canada, 25(5), 281\u2013284.","journal-title":"The Canadian Journal of Infectious Diseases & Medical Microbiology AMMI Canada"},{"key":"240_CR10","unstructured":"Manitoba Health, Seniors and Active Living. Manitoba Tuberculosis Protocol. February 2014. (accessed May 2019 at \nhttp:\/\/www.gov.mb.ca\/health\/publichealth\/cdc\/protocol\/tb.pdf\n\n)."},{"issue":"5","key":"240_CR11","first-page":"424","volume":"67","author":"AC Pettit","year":"2013","unstructured":"Pettit, A. C., Bethel, J., Hirsch-Moverman, Y., Colson, P. W., & Sterling, T. R. (2013). Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. Journal of Information Security, 67(5), 424\u2013432.","journal-title":"Journal of Information Security"},{"key":"240_CR12","unstructured":"Public Health Agency of Canada and the Canadian Thoracic Society and the Canadian Lung Association. Canadian Tuberculosis Standards. 7th edition. February 2014. (accessed May 2019 at \nhttp:\/\/www.phac-aspc.gc.ca\/tbpc-latb\/pubs\/tb-canada-7\/index-eng.php\n\n)."},{"issue":"3","key":"240_CR13","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.17269\/cjph.104.3643","volume":"104","author":"P Rivest","year":"2013","unstructured":"Rivest, P., Street, M. C., & Allard, R. (2013). Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010. Canadian Journal of Public Health, 104(3), e235\u2013e239.","journal-title":"Canadian Journal of Public Health"},{"issue":"12","key":"240_CR14","first-page":"1449","volume":"18","author":"A Rubinowicz","year":"2014","unstructured":"Rubinowicz, A., Bartlett, G., MacGibbon, B., et al. (2014). Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study. The International Journal of Tuberculosis and Lung Disease, 18(12), 1449\u20131454.","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"issue":"3","key":"240_CR15","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.1503\/cmaj.091824","volume":"183","author":"BM Smith","year":"2011","unstructured":"Smith, B. M., Schwartzman, K., Bartlett, G., & Menzies, D. (2011). Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ, 183(3), E173\u2013E179.","journal-title":"CMAJ"},{"issue":"4","key":"240_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/jpids\/pit015","volume":"2","author":"KB Spicer","year":"2013","unstructured":"Spicer, K. B., Perkins, L., DeJesus, B., et al. (2013). Completion of latent tuberculosis therapy in children: impact of country of origin and neighborhood clinics. Journal of the Pediatric Infectious Diseases Society, 2(4), 312\u2013319.","journal-title":"Journal of the Pediatric Infectious Diseases Society"},{"key":"240_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.7326\/M14-1019","volume":"161","author":"HR Stagg","year":"2014","unstructured":"Stagg, H. R., Zenner, D., Harris, R. J., et al. (2014). Treatment of latent tuberculosis infection: a network meta-analysis. Annals of Internal Medicine, 161, 419\u2013428. \nhttps:\/\/doi.org\/10.7326\/M14-1019\n\n.","journal-title":"Annals of Internal Medicine"},{"key":"240_CR18","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling, T. R., Villarino, M. E., Borisov, A. S., et al. (2011). TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. The New England Journal of Medicine, 365, 2155\u20132166.","journal-title":"The New England Journal of Medicine"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-019-00240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.17269\/s41997-019-00240-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-019-00240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T13:40:26Z","timestamp":1596116426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.17269\/s41997-019-00240-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.17269\/s41997-019-00240-1","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"type":"print","value":"0008-4263"},{"type":"electronic","value":"1920-7476"}],"subject":[],"published":{"date-parts":[[2019,7,11]]},"assertion":[{"value":"3 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was provided by the University of Manitoba Health Research Ethics Board and the Manitoba First Nations Health Information Governance Committee, which oversees health research involving First Nations. Approval for data access was provided by the Manitoba Health Information Privacy Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy or Manitoba Health, Seniors and Active Living is intended or should be inferred.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}